Akari Therapeutics Plc announced on March 20, 2025, the appointment of Abizer Gaslightwala as President and Chief Executive Officer, effective April 21, 2025. Mr. Gaslightwala is a biotechnology and pharmaceutical industry veteran with 25 years of experience in developing and commercializing novel medicines.
He joins Akari from Jazz Pharmaceuticals, where he served as Senior Vice President and Franchise Head for US Oncology, responsible for a portfolio of products with total annual sales reaching $1 billion. His experience spans both solid and hematological malignancies.
Samir Patel, MD, the outgoing President and CEO, will remain a member of Akari’s Board of Directors. This leadership transition is intended to bring seasoned oncology expertise to the C-Suite as Akari focuses on its next-generation precision bi-functional Antibody-Drug Conjugates (ADCs) for cancer treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.